The tyrosine kinase inhibitors market will register a CAGR of more than 8% by 2023

Tuesday, January 8, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, Jan. 7, 2019 /PRNewswire/ -- About this marketStrategic alliances to trend in the market. The growing prevalence

of various diseases increases the demand for innovative therapeutics. TKI therapeutics are one of the most reliable therapeutic options for the treatment of cancer and age-related diseases such as RVO. Technavio' s analysts have predicted that the tyrosine
kinase inhibitors market will register a CAGR of more than 8% by 2023.Download the full report: https://www.reportbuyer.com/product/5691278 Market OverviewRecent approvals of TKIsMany TKI therapeutic candidates are gaining approval due to their high safety profile and efficacy. The therapeutics that are in last stage of development are expected to get marketing approval during forecast period.Side effects of TKIsDespite highly efficacious, TKIs are associated with a spectrum of side effects such as fatigue, muscle cramps, nausea, vomiting, and diarrhea.For the detailed list of factors that will drive and challenge the growth of the tyrosine kinase inhibitors market during the 2019-2023, view our report.Competitive LandscapeThe market appears to be fragmented and with the presence of several companies including Novartis and Pfizer the competitive environment is quite intense. Factors such as the rising strategic alliances and the recent approvals of TKIs, will provide considerable growth opportunities to tyrosine kinase inhibitors manufactures. Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson & Johnson, Novartis, and Pfizer are some of the major companies covered in this report.Download the full report: https://www.reportbuyer.com/product/5691278 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: sarah@reportbuyer.com Tel: +1 (718) 213 4904 Website: www.reportbuyer.com

Cision View original content:http://www.prnewswire.com/news-releases/the-tyrosine-kinase-inhibitors-market-will-register-a-cagr-of-more-than-8-by-2023-300773875.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store